Definium Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-02-26
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2022-09-30 was 2.65%, a 6525.00% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2022-06-30 was 2.71%, a 13450.00% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2022-03-31 was 1.79%, a 517.24% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2021-09-30 was 0.04%.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.60%, a 2.86% increase from fiscal 2024.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.50%, a 25.00% increase from fiscal 2023.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 2.80%, a 55.56% increase from fiscal 2022.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.80%, a 500.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 3.60% 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 3.50% 10-K · filed 2026-02-26 | |||
| 2023-12-31 | 2.80% 10-K · filed 2025-03-06 | |||
| 2022-12-31 | 1.80% 10-K · filed 2024-02-28 | |||
| 2022-09-30 | 2.65% 10-Q · filed 2022-11-10 | 1.79% 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 2.71% 10-Q · filed 2022-08-11 | 1.79% 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 1.79% 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | 0.30% 10-K · filed 2023-03-09 | |||
| 2021-09-30 | 0.04% 10-Q · filed 2022-11-10 | 0.02% 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | 0.02% 10-Q · filed 2022-08-11 | 0.02% 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 0.29% 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 0.20% 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |